Keros Therapeutics Q3 2026 Results: Turns Profitable, Net Income $14.2M
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. The filing highlights ongoing Phase 2 trials for rinvatercept (KER-065) and elritercept (KER-050), the latter of which is being developed in collaboration with Takeda and Hansoh.
- Key figure
- Net income $14.2M